Kobenhoved, Denmark
Kobenhoved, Denmark
SEARCH FILTERS
Time filter
Source Type

Wiseguyreports.Com Adds “Ambulatory Surgery Center -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database This report studies the Ambulatory Surgery Center on United States and global market, focuses on the top players in US market and also the market status and outlook by type and application. Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Ambulatory Surgery Center in these regions, from 2012 to 2022 (forecast), covering North America Europe Asia-Pacific South America Middle East and Africa The On the basis of product, the Ambulatory Surgery Center market is primarily split into On the basis on the end users/applications, this report covers Hospital-affiliated ASCs Freestanding ASCs 2017-2022 Ambulatory Surgery Center Report on United States and Global Market, Status and Forecast, by Players, Types and Applications 1 Methodology and Data Source 1.1 Methodology/Research Approach 1.1.1 Research Programs/Design 1.1.2 Market Size Estimation 1.1.3 Market Breakdown and Data Triangulation 1.2 Data Source 2.1.1 Secondary Sources 2.1.2 Primary Sources 1.3 Disclaimer 7 United States Ambulatory Surgery Center Players Profiles/Analysis 7.1 AmSurg 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 AmSurg Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.1.4 Main Business/Business Overview 7.2 United Surgical Partners 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 United Surgical Partners Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.2.4 Main Business/Business Overview 7.3 Surgery Partners 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 Surgery Partners Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.3.4 Main Business/Business Overview 7.4 Surgical Care Affiliates 7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.4.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.4.2.1 Product A 7.4.2.2 Product A 7.4.3 Surgical Care Affiliates Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.4.4 Main Business/Business Overview 7.5 Envision Healthcare 7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.5.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.5.2.1 Product A 7.5.2.2 Product B 7.5.3 Envision Healthcare Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.5.4 Main Business/Business Overview 7.6 Mednax 7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.6.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.6.2.1 Product A 7.6.2.2 Product B 7.6.3 Mednax Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.6.4 Main Business/Business Overview 7.7 Tenet Healthcare 7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.7.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.7.2.1 Product A 7.7.2.2 Product B 7.7.3 Tenet Healthcare Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.7.4 Main Business/Business Overview 7.8 Team Health 7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.8.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.8.2.1 Product A 7.8.2.2 Product B 7.8.3 Team Health Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.8.4 Main Business/Business Overview 7.9 HCA Healthcare 7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.9.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.9.2.1 Product A 7.9.2.2 Product B 7.9.3 HCA Healthcare Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.9.4 Main Business/Business Overview 7.10 Symbion 7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.10.2 Ambulatory Surgery Center Product Category, End Uses and Specification 7.10.2.1 Type A 7.10.2.2 Type B 7.10.3 Symbion Ambulatory Surgery Center Sales (K Units), Revenue (Million USD), Price (USD/Unit), Gross Margin (%) and Market Share (%) (2012-2017) 7.10.4 Main Business/Business Overview 7.11 SurgCenter Development 7.12 Suprabha Surgicare 7.13 ASCOA 7.14 Nueterra Healthcare For more information, please visit https://www.wiseguyreports.com/sample-request/1235962-2017-2022-ambulatory-surgery-center-report-on-united-states-and-global


News Article | May 15, 2017
Site: www.businesswire.com

MIAMI--(BUSINESS WIRE)--H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with over $21 billion of equity capital under management is pleased to announce that it has entered into an agreement to sell its existing stake in Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) to Bain Capital Private Equity, a leading global private investment firm. In conjunction with the transaction, Surgery Partners and National Surgical Healthcare (“NSH”), an owner and operator of surgical facilities in partnership with local physicians, have entered into a definitive merger agreement under which Surgery Partners will acquire NSH from Irving Place Capital for approximately $760 million. Funding for the transaction will be provided in part by Bain Capital Private Equity, who is injecting capital in exchange for preferred equity in the Company. In December 2009, H.I.G. partnered with Surgery Partners CEO Mike Doyle to acquire Surgery Partners, which at the time operated a small portfolio of ambulatory surgery centers and physician practices in Florida. With the leadership of Mike Doyle and the Surgery Partners team and strategic guidance and capital support from H.I.G., the Company executed upon an aggressive growth plan, expanding its footprint across the country and enhancing its specialty mix and ancillary service offerings, through both organic growth and acquisitions, including the acquisitions of Symbion and NovaMed. In 2015, Surgery Partners underwent an initial public offering on the NASDAQ exchange, with H.I.G. retaining a majority equity stake in the Company. The combined Surgery Partners and NSH company will operate 125 surgical facilities, 58 physician practice locations and complementary ancillary services in 32 states. Mike Doyle, CEO of Surgery Partners, said, “We are thankful to have had the opportunity to grow the Company with H.I.G. Capital over the past seven years, and thank the entire H.I.G. team for their support of our Company and management team along the way.” H.I.G. Capital Managing Director Matthew Lozow commented, “Surgery Partners is an exceptional company and we are grateful to Mike Doyle and the entire Surgery Partners organization for all their contributions in building this tremendous platform over the past several years. We are proud of what this team has accomplished during our partnership together and look forward to watching the Company’s continued success in the future.” Headquartered in Nashville, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 150 locations in 29 states, including ambulatory surgical facilities, surgical hospitals, a diagnostic laboratory, multi-specialty physician practices and urgent care facilities. For information about Surgery Partners, visit the company’s website at www.surgerypartners.com. H.I.G. is a leading global private equity and alternative assets investment firm with over $21 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Mexico City and Rio de Janeiro, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach: Since its founding in 1993, H.I.G. has invested in and managed more than 200 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com. NSH is an innovative healthcare partner that empowers physicians to thrive in a changing marketplace. NSH owns and operates 21 surgical facilities, specializing in orthopedic surgery, spine and back, pain management, and neurosurgery. For information about NSH, visit the company’s website at www.nshinc.com. Bain Capital Private Equity (www.baincapitalprivateequity.com) has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since our founding in 1984. Our team of more than 220 investment professionals creates value for our portfolio companies through our global platform and depth of expertise in key vertical industries, including industrials, consumer/retail, financial and business services, healthcare, and technology, media and telecommunications. In addition to private equity, Bain Capital invests across asset classes including credit, public equity and venture capital, and leverages the firm’s shared platform to capture opportunities in strategic areas of focus. Since its founding in 1997, Irving Place Capital has invested in over 60 portfolio companies, primarily in the industrial, packaging, consumer and retail industries. The firm focuses on making control or entrepreneur-driven investments where it can apply its substantial operating and strategic resources and expertise to enhance value. Irving Place Capital has successfully executed a broad range of transactions, including buyouts, recapitalizations, build-ups, corporate divestitures, take-privates and distressed-to-control situations. Irving Place Capital generally seeks to invest in companies headquartered in North America or Western Europe. More information about Irving Place Capital is available at www.irvingplacecapital.com.


Trojel-Hansen C.,Rigshospitalet 3731 | Erichsen K.D.,Symbion Inc. | Christensen M.K.,Symbion Inc. | Jensen P.B.,Symbion Inc. | And 2 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2011

Background: Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific transporters. Deprivation of intracellular amino acids or block of amino acid uptake has been shown to be cytotoxic to many established human cancer cell lines in vitro and in human cancer xenograft models. Results: In this paper, we provide evidence that the two small molecule oxyphenisatine analogs TOP001 and TOP216 exert their anti-cancer effect by affecting tumor cell metabolism and inducing intracellular amino acid deprivation, leading to a block of cell proliferation. GCN2-mediated phosphorylation of eIF2α as well as mTOR pathway inhibition supports the above notion. In addition, these novel anti-cancer compounds inhibit DNA and protein synthesis and induce apoptosis in a broad spectrum of cancer cell lines. In vivo, the compounds induce tumor stasis and regression in mouse xenograft models of human breast, prostate, ovarian and pancreatic cancer, both when administered intravenously and orally. Conclusion: In conclusion, these small molecules, built on a 1,3-dihydroindole-2-one scaffold, elicit strong anti-proliferative and cytotoxic activity, and importantly, a strong anti-tumorigenicity is observed in in vivo xenograft models of human breast, ovary, prostate and pancreatic cancers encouraging the translation of this class of compounds into the clinic. © 2010 Springer-Verlag.


Doyle W.M.,Symbion Inc. | Power M.A.,Symbion Inc.
Proceedings of the Annual ISA Analysis Division Symposium | Year: 2010

This paper describes a software approach designed to accelerate process analytical development and deployment by standardizing the interactions with diverse instruments, sampling systems, chemometric packages, and enterprise data systems and by integrating all required functionality at the analyzer level. In addition to the required control and data analysis functions, the system provides local displays in various formats, including statistical information and real-time trend plots, as well as database storage, alarms, and remote communications. It can be implemented on a standard PC or integrated into a dedicated process analytical "appliance" for locked-down deployment.


Kelly J.M.,London School of Hygiene and Tropical Medicine | Taylor M.C.,London School of Hygiene and Tropical Medicine | Horn D.,London School of Hygiene and Tropical Medicine | Loza E.,Latvian Institute of Organic Synthesis | And 3 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2012

A number of hydroxamic acid derivatives which inhibit human histone deacetylases were investigated for efficacy against cultured bloodstream form Trypanosoma brucei. Three out of the four classes tested displayed significant activity. The majority of compounds blocked parasite growth in the submicromolar range. The most potent was a member of the sulphonepiperazine series with an IC 50 of 34 nM. These results identify lead compounds with potential for the development of a novel class of trypanocidal agent. © 2012 Elsevier Ltd. All rights reserved.


Christensen M.K.,Symbion Inc. | Erichsen K.D.,Symbion Inc. | Trojel-Hansen C.,Symbion Inc. | Trojel-Hansen C.,Copenhagen University | And 14 more authors.
Journal of Medicinal Chemistry | Year: 2010

Optimization of the anticancer activity for a class of compounds built on a 1,3-dihydroindole-2-one scaffold was performed. In comparison with recently published derivatives of oxyphenisatin the new analogues exhibited an equally potent antiproliferative activity in vitro and improved tolerability and activity in vivo. The best compounds from this series showed low nanomolar antiproliferative activity toward a series of cancer cell lines (compound (S)-38: IC50 of 0.48 and 2 nM in MCF-7 (breast) and PC3 (prostate), respectively) and potent antitumor effects in well tolerated doses in xenograft models. The racemic compound (RS)-38 showed complete tumor regression at a dose of 20 mg/kg administered iv on days 1 and 7 in a PC3 rat xenograft. © 2010 American Chemical Society.


A process control method that automatically and comprehensively manages the creation, storage and use of electronic records during the operation of a controlled process and for governing and documenting the users that operate the computer systems that are involved in the creation, storage and use of the electronic records. The method controls a process, such as a chemical process, by receiving measurement information relating to the process, applying rules to the received measurement information to determine a desired response, and sending control information to at least one device associated with the process, so as to modify the process. The method maintains the rules, measurements and control activity in transaction logs or audit trails related thereto in a secure database. By providing convenient, centralized control of the process within a secure database, the method enhances compliance with the FDA regulations that permit electronic records to be regarded as the equivalent to paper records under 21 CFR Part 11.


a method for global deployment of analytical methods and merging of data via mobile technology and remote mobile devices, the method comprising: developing analytical methods for quantification and identification to be stored in a relational database and distributed to remote mobile devices; developing execution methods to be stored in a relational database and distributed to remote mobile devices; employing a methodology incorporating gatekeeper applications to ensure full control and traceability in the development, deployment, and use of the analytical methods and the processing and distribution of data and analytical predictions; collecting field data from remote devices to a central relational database for a posterior analysis, model enhancement, and archiving; providing remote distributed access to all stored data including field data and processed data; providing a database methodology that provides for a highly level of security for the transmission of data and the storage of data; and providing a robust networking strategy to accommodate for potentially unreliable and unstable network connections


A process control method that automatically and comprehensively manages the creation, storage and use of electronic records during the operation of a controlled process and for governing and documenting the users that operate the computer systems that are involved in the creation, storage and use of the electronic records. The method controls a process, such as a chemical process, by receiving measurement information relating to the process, applying rules to the received measurement information to determine a desired response, and sending control information to at least one device associated with the process, so as to modify the process. The method maintains the rules, measurements and control activity in transaction logs or audit trails related thereto in a secure database. By providing convenient, centralized control of the process within a secure database, the method enhances compliance with the FDA regulations that permit electronic records to be regarded as the equivalent to paper records under 21 CFR Part 11.


Loading Symbion Inc. collaborators
Loading Symbion Inc. collaborators